CAMBRIDGE, Mass. — For Dr. Jeff Jonas, the desire to understand complex mechanics extends from how drugs reach brain receptors to the design of a well-run clinical trial to the craftsmanship that goes into a first-class watch, of which he owns many.
“This is a Rolex, a new Daytona, which is hard to get,” Jonas was saying of the piece on his wrist the other day, racing through his mile-a-minute, no-need-to-complete-a-sentence explanation. “They have an ultrahard piece of ceramic, which is their big innovation, plus they have a clutch system in the chronograph, which makes it very accurate, so the shape of the clutch, whether it’s vertical or horizontal, it’s all — and some guy does this.”
Jonas himself is the guy in charge of Sage Therapeutics, a company fresh off positive clinical trial results for drugs to treat two forms of depression and pushing ahead with its aim of getting medicines for central nervous system disorders approved.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect